← Back to Search

Patient Education for Prostate Cancer

Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of metastatic prostatic adenocarcinoma
Receiving luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist therapy continuously for at least 1 year with anticipated lifelong therapy
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial will help to assess how an educational intervention on orchiectomy affects the number of patients willing to have the surgery.

Who is the study for?
This trial is for men with advanced prostate cancer who have been on hormone therapy for at least a year and expect to continue it. They must be able to fill out surveys in English. Men who've had more than two types of systemic treatments besides castration can't join.Check my eligibility
What is being tested?
The study is looking into the effects of educating patients about orchiectomy, which is surgery to remove the testicles, as an alternative to ongoing medical hormone-blocking treatments for prostate cancer.See study design
What are the potential side effects?
Since this trial focuses on education rather than medication or surgical intervention, there are no direct side effects from the educational material itself.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I have been diagnosed with advanced prostate cancer.
I have been on hormone therapy for over a year and expect to continue.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients that undergo orchiectomy after receiving study education intervention
Secondary outcome measures
Change in body image perception using the Hopwood BIS questionnaire in patients undergoing versus not undergoing orchiectomy.
Change in sexuality measured using the PROMIS v2.0 questionnaire in patients undergoing versus not undergoing orchiectomy.
Comparison of costs of medical versus surgical castration
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Educational InterventionExperimental Treatment1 Intervention
Participants in this arm undergo a short educational session about orchiectomy. They will also be asked to complete questionnaires.
Group II: No InterventionActive Control1 Intervention
Participants that decline the education session will continue with routine care of their cancer. They will also be asked to complete questionnaires.
First Studied
Drug Approval Stage
How many patients have taken this drug
Patient Education

Find a Location

Who is running the clinical trial?

University of ChicagoLead Sponsor
1,017 Previous Clinical Trials
734,419 Total Patients Enrolled
21 Trials studying Prostate Cancer
8,240 Patients Enrolled for Prostate Cancer
Walter Stadler, MDStudy ChairUniversity of Chicago
4 Previous Clinical Trials
108 Total Patients Enrolled
2 Trials studying Prostate Cancer
18 Patients Enrolled for Prostate Cancer

Media Library

Patient Education Clinical Trial Eligibility Overview. Trial Name: NCT04705038 — N/A
Prostate Cancer Research Study Groups: Educational Intervention, No Intervention
Prostate Cancer Clinical Trial 2023: Patient Education Highlights & Side Effects. Trial Name: NCT04705038 — N/A
Patient Education 2023 Treatment Timeline for Medical Study. Trial Name: NCT04705038 — N/A
~29 spots leftby Dec 2025